Viveve Medical, Inc.
Viveve Medical, Inc. (VIVE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
vive · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.00
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.00 | ↑ 3.66% |
1-day model range: $0–$0. Peak: $0 (+3.66%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · VIVE · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2020-11-25 | Raymond James | Downgrade ↓ | Outperform→Perform |
| 2020-11-25 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2020-11-25 | Ladenburg Thalmann | Downgrade ↓ | Buy→Neutral |
| 2020-11-25 | Mizuho Securities | Downgrade ↓ | Buy→Underperform |
| 2020-11-25 | Stifel Nicolaus | Downgrade ↓ | Buy→Hold |
| 2020-11-25 | Mizuho | Downgrade ↓ | Buy→Underperform |
| 2020-11-25 | Raymond James | Maintains | Outperform→Outperform |
| 2020-11-25 | Ladenburg Thalmann | Upgrade ↑ | Neutral→Buy |
| 2019-12-03 | Ladenburg Thalmann | Upgrade ↑ | Neutral→Buy |
| 2019-07-24 | Ladenburg Thalmann | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on Viveve Medical, Inc. (VIVE) stock. Of the recent 25 rating actions, 2 were upgrades and 13 were downgrades. 10 analysts currently cover VIVE.
Analyst Recommendation Trends
VIVE analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$6M
↓ 42.4% YoY
Revenue Next Year
$7M
↑ 7.4% YoY
EPS This Year
$-2.52
EPS Next Year
$-2.55
↑ 1.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast VIVE EPS of $-2.52 for the current fiscal year, based on estimates from 3 analysts. The VIVE revenue forecast is $6M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The VIVE stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VIVE price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The VIVE short-term stock prediction for tomorrow is $0.00 (+3.66%).
Viveve Medical, Inc. trades on OTC under the ticker VIVE. The VIVE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
VIVE forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month VIVE price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.